Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics, Inc. reported that its Chief Accounting Officer, Katharine Peterson, received a grant of stock options covering 31,900 shares of common stock. The options were awarded on March 1, 2026 at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, 25% of the option shares vest on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments after that date. Vesting in all cases requires Ms. Peterson to remain in continuous service through each vesting date.
Acrivon Therapeutics Chief Medical Officer Mirza Mansoor Raza received a grant of stock options covering 174,068 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase. According to the vesting schedule, 25% of the shares vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service through each vesting date. Following this award, he holds options on 174,068 shares directly.
Miller Mary reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received a grant of stock options covering 129,760 shares of common stock on March 1, 2026. According to the vesting terms, 25% of these options vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, all conditioned on her continued service through each vesting date.
Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received a grant of stock options. The award covers 132,925 options with an exercise price of $0.00 per share, characterized as a grant or award acquisition rather than an open-market purchase.
According to the vesting terms, 25% of the options vest on March 1, 2027, and the remaining options vest in 36 substantially equal monthly installments after that date. All vesting requires Mr. Levy to remain in continuous service with the company through each vesting date.
Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics granted Chief Development Officer Erick Gamelin a stock option covering 94,946 shares of common stock. The award is reported as a direct beneficial holding at a stated price of $0.0000 per option unit.
According to the vesting terms, 25% of the shares subject to the option vest on March 1, 2027. The remaining shares vest in 36 substantially equal monthly installments after that date, conditioned on Gamelin’s continuous service through each vesting date.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe received a grant of stock options covering 186,728 shares of common stock. The Form 4 classifies this as a grant or award acquisition, not an open-market purchase or sale.
According to the vesting terms, 25% of the option vests on March 1, 2027, and the remaining shares vest in 36 substantially equal monthly installments thereafter, provided Devroe remains in continuous service through each vesting date.
Acrivon Therapeutics reported stock option awards to senior executives. The filing shows grants covering 417,210 options and 185,495 options, with exercise rights structured as long-term incentives rather than cash purchases. Twenty-five percent of each grant vests on
Acrivon Therapeutics, Inc. is shifting its ACR-368 OncoSignature diagnostic testing fully in-house after completing and certifying an internally owned Clinical Laboratory Improvement Amendment (CLIA) laboratory in Watertown, Massachusetts. This new lab is intended to support development of the company’s current and future targeted therapies.
On February 25, 2026, Acrivon and Akoya Biosciences, a wholly owned subsidiary of Quanterix Corporation, entered into a Termination and Transition Agreement to mutually end their June 17, 2022 OncoSignature Companion Diagnostic Agreement. The termination involves no financial payments between the parties. Quanterix and Acrivon agreed on a transition plan so procedures, materials and know-how from Akoya’s prior ACR-368 OncoSignature work are transferred to Acrivon, while Quanterix continues clinical testing during the changeover to support Acrivon’s registrational-intent Phase 2b study. Effective immediately, Acrivon holds full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
Acrivon Therapeutics described interim Phase 2b data for its CHK1/2 inhibitor ACR-368 in endometrial cancer during a company-sponsored key opinion leader panel held at the ESGO Congress. The trial uses the ACR-368 OncoSignature biomarker to prospectively select patients predicted to benefit.
In the biomarker-positive Arm 1, ACR-368 monotherapy showed an objective response rate of 39% (95% CI, 24–56) in 31 treated subjects, with disease control rate of 80.6% and 16‑week clinical benefit rate of 61.3%. Across arms, better response rates were observed in patients with ≤2 prior lines of therapy, including serous and non‑serous histologies.
Safety data showed mainly hematologic adverse events such as thrombocytopenia, anemia, leukopenia and neutropenia, with no fatal treatment-related events and a notable absence of common non‑hematologic toxicities. The study is expanding to additional U.S. and European sites, with enrollment completion for the serous all‑comer cohort targeted in Q4 2026.
Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen. The company withheld 14,265 shares of common stock at